Board Changes

Oncimmune Holdings PLC

01 August 2023

 

1 August 2023

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Changes to the Board

Oncimmune Holdings plc (AIM: ONC.L), the leading autoantibody profiling company to the pharmaceutical and biotechnology industry, is pleased to announce that Martin Gouldstone has today started as the Company's new Chief Executive Officer and joined the Board of Directors.

With Martin as Chief Executive Officer, Ron Kirschner, who was appointed as acting Chief Executive Officer in June, will be taking up the role of Chief Operating Officer and has stepped down from the Board.  Ron remains Oncimmune's Company Secretary.

Regulatory disclosures in relation to Martin Gouldstone's appointment, as required under Schedule 2(g) of the AIM Rules for Companies, were contained in the Company's announcement on 12 July 2023 and have not changed as at the date of this announcement.

For further information:

Oncimmune Holdings plc

[e-mail]

Singer Capital Markets (Nominated Adviser and Broker)

Phil Davies, Harry Gooden, George Tzimas, James Fischer

[phone]

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

[phone]

[phone]

About Oncimmune

Oncimmune is a specialist pharmaceutical services company, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a contract discovery and development service business whose ImmunoINSIGHTS platform delivers actionable insights into therapies to the Company's pharmaceutical and biotech partners.

Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients. Oncimmune's ImmunoINSIGHTS service business at its discovery research centre in Dortmund, Germany. The ImmunoINSIGHTS business development team are based in the US and Europe.

For more information, visit www.oncimmune.com

 

END